Search Results - Xiangyi KONG

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II by Chuqi Lei, Xiangyi Kong, Xiangyi Kong, Ryan J. Sullivan, Caisheng Wu, Caisheng Wu, Dawei Wang, Lin Zhang, Lin Zhang, Lin Zhang

Connect to this object online.

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism by Hao Dong, Yihang Qi, Xiangyi Kong, Zhongzhao Wang, Yi Fang, Jing Wang

Connect to this object online.

Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies by Xiangyi Kong, Hao Deng, Shun Gong, Theodore Alston, Yanguo Kong, Jingping Wang

Connect to this object online.

Omitting ALND Is Not Safe for a Cohort of Early-Stage Breast Cancer Patients with 1-2 SLNs Macro-Metastases and Breast-Conserving Therapy: A Single-Center Retrospective Study by Xiangyu WANG, Yinqi GAO, Xue YANG, Xiangyi KONG, Zixing WANG, Yi FANG, Jing WANG

Connect to this object online.

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I by Xiangyi Kong, Ryan J Sullivan, Caisheng Wu, Lin Zhang, Lin Zhang, Lin Zhang, Yu Jiang

Connect to this object online.

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases by Ke Zhang, Xiangyi Kong, Yuan Li, Zhongzhao Wang, Lin Zhang, Lin Zhang, Lin Zhang, Lixue Xuan

Connect to this object online.

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence by Yihang Qi, Lin Zhang, Lin Zhang, Lin Zhang, Zhongzhao Wang, Xiangyi Kong, Jie Zhai, Yi Fang, Jing Wang

Connect to this object online.

Hypertension Induced by Combination Therapy of Cancer: A Systematic Review and Meta-Analysis of Global Clinical Trials by Xiaodan Guo, Xiaoyu Qian, Ying Jin, Xiangyi Kong, Zhihong Qi, Tie Cai, Lin Zhang, Lin Zhang, Caisheng Wu, Weihua Li

Connect to this object online.

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer by Yihang Qi, Yihang Qi, Wenxiang Zhang, Ray Jiang, Olivia Xu, Xiangyi Kong, Lin Zhang, Lin Zhang, Lin Zhang, Yi Fang, Jingping Wang, Jing Wang

Connect to this object online.